8/1/2013

Prescribers should be involved in deciding whether and how risks of certain classes of drugs and biologics will be mitigated in risk evaluation and mitigation strategies, the AAFP's Ann Karty, M.D., told an FDA meeting on the challenges of REMS standardization and assessment. Karty, who presented information on REMS requirements for extended-release and long-acting opioids, said that REMS continuing medical education should remain voluntary for prescribers and that mandating CME could create confusion for physicians and limit patient access to drugs.

Full Story:
AAFP News

Related Summaries